The present invention discloses and claims compounds of formula (I) and formula (II), ##STR00001## as inhibitors of human casein kinase I.epsilon. and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula (II) are also disclosed and claimed.
Claims What is claimed is: 1. A compound of formula (I) or formula (II) ##STR00026## wherein X is S or S(O).sub.n; R.sub.1 is H or C.sub.1-C.sub.6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is H, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, aryl-(C.sub.1-C.sub.6alkyl), heterocycle-(C.sub.1-C.sub.6alkyl), C.sub.1-C.sub.6alkoxy, aryl-(C.sub.1-C.sub.6alkoxy), heterocycle-(C.sub.1-C.sub.6alkoxy), CF.sub.3, halogen, SH, C.sub.1-6alkylthio, aryl-(C.sub.1-C.sub.6alkylthio), heterocycle-(C.sub.1-C.sub.6alkylthio), NO.sub.2, NH.sub.2, NR.sub.5R.sub.6, aryl-(C.sub.1-C.sub.6alkylamino), heterocycle-(C.sub.1-C.sub.6alkylamino), or XR.sub.3 wherein X and R.sub.3 are as defined above; R.sub.5 is H or C.sub.1-C.sub.6alkyl; R.sub.6 is H or C.sub.1-C.sub.6alkyl; L is N or CR.sub.7 wherein R.sub.7 is H or C.sub.1-C.sub.6alkyl; M is S, O or NR.sub.8 wherein R.sub.8 is H, C.sub.1-C.sub.6alkyl, aryl-(C.sub.1-C.sub.6alkyl), heterocycle-(C.sub.1-C.sub.6alkyl) or acyl; n is 1 or 2; or a stereoisomer, an enantiomer, a racemate or a tautomer thereof; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 of formula (I) or formula (II) wherein M and X are each S. 3. The compound according to claim 2 of formula (I) wherein L is CR.sub.7. 4. The compound according to claim 3 wherein R.sub.7 is H. 5. The compound according to claim 4 selected from the group consisting of: 6-phenylsulfanyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(3-fluorophenyl-sulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(4-chlorophenyl-sulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(2-aminophenyl-sulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(pyridin-2-ylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-p-tolylsulfanyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(thiophen-2-yl-sulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(3,5-dichloro-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxyl- ic acid amide, 6-(pyridin-4-ylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-m-tolylsulfanyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-o-tolylsulfanyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(2,3-dichloro-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(2,5-dichloro-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxyl- ic acid amide, 6-(2-ethyl-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(3-bromo-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(3,5-dimethyl-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(3-methoxy-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(2-methoxy-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, 6-(2-trifluoromethyl-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-car- boxylic acid amide, 6-(2-fluoro-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid amide, and 6-(3-trifluoromethoxy-phenylsulfanyl)-4H-thieno[3,2-b]pyrrole-5-carboxyli- c acid amide. 6. The compound according to claim 2 of formula (I) wherein L is N. 7. The compound according to claim 6 selected from the group consisting of: 6-phenylsulfanyl-4H-pyrrolo[2,3-d]thiazole-5-carboxylic acid amide, 6-(3-fluoro-phenylsulfanyl)-4H-pyrrolo[2,3-d]thiazole-5-carboxylic acid amide, and 6-(pyridin-2-ylsulfanyl)-4H-pyrrolo[2,3-d]thiazole-5-carboxylic acid amide. 8. The compound according to claim 2 of formula (II) wherein L is CR.sub.7. 9. The compound according to claim 8 wherein R.sub.7 is H. 10. The compound according to claim 9 selected from the group consisting of: 4-(pyridin-2-ylsulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(phenylsulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 6-(3-fluorophenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(pyridin-4-ylsulfanyl)-6H-thieno[2,3-b]-pyrrole-5-carboxylic acid amide, 4-(3,5-dichlorophenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxyl- ic acid amide, 4-(thiophen-2-yl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(3-bromophenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(3-methoxyphenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(2-methoxyphenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, 4-(3-chlorophenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide, and 4-(3-methylphenyl-sulfanyl)-6H-thieno[2,3-b]pyrrole-5-carboxylic acid amide. 11. The compound according to claim 2 of formula (II) wherein L is N. 12. The compound according to claim 11 selected from the group consisting of: 2-methyl-6-phenyl-sulfanyl-4H-pyrrolo[3,2-d]thiazole-5-carboxylic acid amide, 6-(3-methoxyphenyl-sulfanyl)-2-methyl-4H-pyrrolo[3,2-d]thiazole-5-carboxy- lic acid amide, 6-(3-fluorophenyl-sulfanyl)-2-methyl-4H-pyrrolo[3,2-d]thiazole-5-carboxyl- ic acid amide, 6-(3-chlorophenyl-sulfanyl)-2-methyl-4H-pyrrolo[3,2-d]thiazole-5-carboxyl- ic acid amide, 6-(3-trifluoromethoxy-phenylsulfanyl)-2-methyl-4H-pyrrolo[3,2-d]thiazole-- 5-carboxylic acid amide, 2,6-bis-phenylsulfanyl-4H-pyrrolo[3,2-d]thiazole-5-carboxylic acid amide, 2,6-bis-(3-methoxy-phenylsulfanyl)-4H-pyrrolo[3,2-d]thiazole-5-carboxylic acid amide, 6-phenylsulfanyl-4H-pyrrolo[3,2-d]thiazole-5-carboxylic acid amide, and 6-(3-methoxyphenyl-sulfanyl)-4H-pyrrolo[3,2-d]thiazole-5-carboxylic acid amide. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I) or formula (II) according to claim 1, or a stereoisomer, an enantiomer, a racemate or a tautomer of said compound; or a pharmaceutically acceptable salt thereof. 14. A method for inhibiting casein kinase I.epsilon. activity in a patient comprising the administration to said patient of a therapeutically effective amount of a compound of formula (I) or formula (II), ##STR00027## wherein X is S or S(O).sub.n; R.sub.1 is H or C.sub.1-C.sub.6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is H, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, aryl-(C.sub.1-C.sub.6alkyl), heterocycle-(C.sub.1-C.sub.6alkyl), C.sub.1-C.sub.6alkoxy, aryl-(C.sub.1-C.sub.6alkoxy), heterocycle-(C.sub.1-C.sub.6alkoxy), CF.sub.3, halogen, SH, C.sub.1-6alkylthio, aryl-(C.sub.1-C.sub.6alkylthio), heterocycle-(C.sub.1-C.sub.6alkylthio), NO.sub.2, NH.sub.2, NR.sub.5R.sub.6, aryl-(C.sub.1-C.sub.6alkylamino), heterocycle-(C.sub.1-C.sub.6alkylamino), or XR.sub.3 wherein X and R.sub.3 are as defined above; R.sub.5 is H or C.sub.1-C.sub.6alkyl; R.sub.6 is H or C.sub.1-C.sub.6alkyl; L is N or CR.sub.7 wherein R.sub.7 is H or C.sub.1-C.sub.6alkyl; M is S, O or NR.sub.8 wherein R.sub.8 is H, C.sub.1-C.sub.6alkyl, aryl-(C.sub.1-C.sub.6alkyl), heterocycle-(C.sub.1-C.sub.6alkyl) or acyl; n is 1 or 2; or a stereoisomer, an enantiomer, a racemate or a tautomer thereof; or a pharmaceutically acceptable salt thereof. 15. A process for the preparation of a compound of formula (I) or formula (II) ##STR00028## wherein: X is S; R.sub.1 is H or C.sub.1-C.sub.6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is XR.sub.3 wherein X and R.sub.3 are as defined above; R.sub.5 is H or C.sub.1-C.sub.6alkyl; R.sub.6 is H or C.sub.1-C.sub.6alkyl; L is N; M is S, O or NR.sub.8 wherein R.sub.8 is C.sub.1-C.sub.6alkyl, aryl-(C.sub.1-C.sub.6alkyl), heterocycle-(C.sub.1-C.sub.6alkyl) or acyl; comprising: reacting a compound of formula 10 or formula 13 wherein R.sub.4 is halogen and R.sub.2 is as defined above ##STR00029## with a diaryldisulfide or a diheterocycledisulfide in the presence of a suitable base in a suitable polar solvent, and isolating the compound of formula (I) or formula (II) as defined above wherein R.sub.4 is XR.sub.3. 16. The process of claim 15 wherein R.sub.4 of the compound of formula 10 or formula 13 is bromine, the base is cesium carbonate, the polar solvent is dimethylformamide, and said reaction is carried out at a temperature in the range of from about 80.degree. C. to about 120.degree. C., for a period of time of from about one hour to about 6 hours. 